

Drug/Medical Device Report

Aspreva Pharmaceuticals Corporation (ASPV)

1. Abstract


This report examines the Drug/Medical Device pipeline of Aspreva Pharmaceuticals Corporation (ASPV), detailing each drug/device's indication, clinical trial status, and mechanism of action. Furthermore, this report identifies the Focus Sector of Aspreva Pharmaceuticals Corporation (ASPV), and analyzes its pipeline and performance against the Focus Sector to which it belongs. In summary, this Drug/Medical Device Report makes available 3 key pieces of data that help determine the performance and risk of Biotech, Pharmaceutical and Medical Device companies: (1) product/candidate pipeline, (2) product/candidate clinical trial status, and (3) product/candidate pipeline diversification.

2. Lines of Business Summary

- Aspreva Pharmaceuticals Corporation (ASPV) ranks 1 by market cap among the 9 companies focused in Healthcare > Biopharmaceuticals > Immunology and ranks 54 among all 191 companies participating in Immunology.
- Aspreva Pharmaceuticals Corporation (ASPV) ranks 66 by market cap among the 381 companies focused in Healthcare > Biopharmaceuticals and ranks 99 among all 489 companies participating in Biopharmaceuticals.
- Aspreva Pharmaceuticals Corporation (ASPV) has a Drug pipeline that is diversified across 5 of 21 disease sectors within Biopharmaceuticals.

ASPV: Product Hierarchy Participation	Focus	ASPV Products by Sector	Companies	Focused Companies
I Healthcare	P	1	1064	930
■ Biopharmaceuticals	P	1	489	381
◆ Cardiovascular System	-	0	163	20
◆ Dermatology	-	0	95	8
◆ Immunology	F	0	191	9
◆ Neurology	-	0	184	34
◆ Transplantation	-	1	39	2

3. Sector Performance



Name	Ticker	Last Price	Daily Return %	1 Month Return %	3 Month Return %	1 Year Return %	YTD Return %
Aspreva Pharmaceuticals Corporation	ASPV	26.01	0.00%	0.97%	16.64%	30.84%	0.04%
Biopharmaceuticals	^BPHRM	402.12	-0.47%	-0.49%	-4.85%	-6.04%	1.17%
Immunology	^IMMUN	47.77	-0.55%	-2.37%	-3.40%	-1.98%	-1.02%
Autoimmune Disorders	^228157	136.05	0.10%	0.77%	9.82%	28.12%	0.06%

Recent Leaders and Laggards: Healthcare

Gainers

Name	Ticker	Market Cap.	3 Month Return %
Aspreva Pharmaceuticals Corporation	ASPV	916.399	16.64%

Decliners


Name	Ticker	Market Cap.	3 Month Return %
Genelabs Technologies	GNLB	64.168	-28.71%
La Jolla Pharmaceutical Company	LJPC	146.940	-7.94%

4. Pipeline Summary

Biopharmaceuticals

	ASPV	^BPHRM	^IMMUN	^228157
Approved	3	13	4	3
Approval Pending	0	2	1	1
Phase III	2	3	2	2
Phase II	0	5	2	3
Phase I	0	4	2	0
Preclinical/Research	3	5	2	0
Total Indications	5	16	4	3
Drugs	1	11	3	2

The chart and table compare the number of drug indications in each stage of development for ASPV to the median number of drug indications in each stage of development for its sectors (Focused companies only).



5. Late Stage Drug Candidates

Drug [Stage] Indication Drug Competition by Indication	Expected PDUFA PMA [Proven PMA?] Drug Competition by PMA
CellCept (Mycophenolate Mofetil) [Phase III] Indication: Lupus Nephritis In Systemic Lupus Erythematosus (SLE) Competitors: <ul style="list-style-type: none"> - Biogen Idec Inc. (BIIB) / Rituxan (Rituximab) - Human Genome Sciences (HGS) / LymphoStat-B (Belimumab) - Roche Holding Ltd. (ADR) (RHHBY) / CellCept (Mycophenolate Mofetil) - Roche Holding Ltd. (ADR) (RHHBY) / Rituxan (Rituximab) - Genentech, Inc. (DNA) / Rituxan (Rituximab) <p>More: 9 companies; 9 drugs (not shown)</p>	Expected PDUFA: - PMA: Immunosuppressants Proven: no Competitors: <ul style="list-style-type: none"> - Roche Holding Ltd. (ADR) (RHHBY) / CellCept (Mycophenolate Mofetil) - Teva Pharmaceutical Industries Ltd (ADR) (TEVA) / Hydroxychloroquine Sulfate - Mylan Inc. (MYL) / Hydroxychloroquine Sulfate - Novartis AG (ADR) (NVS) / Sandoz Hydroxychloroquine Sulfate - Interpharm Holdings, Inc. (IPA) / Prednisone
CellCept (Mycophenolate Mofetil) [Phase III] Indication: Pemphigus Vulgaris Competitors: <ul style="list-style-type: none"> - Schering-Plough Corporation (SGP) / Celestone (Glucocorticoid/Betamethasone) - Perrigo Company (PRGO) / Betamethasone Dipropionate - Perrigo Company (PRGO) / Desonide - Perrigo Company (PRGO) / Fluticasone Propionate - Perrigo Company (PRGO) / Hydrocortisone Cream/Ointment <p>More: 1 companies; 2 drugs (not shown)</p>	Expected PDUFA: - PMA: Immunosuppressants Proven: no Competitors: <ul style="list-style-type: none"> - Roche Holding Ltd. (ADR) (RHHBY) / CellCept (Mycophenolate Mofetil) - Teva Pharmaceutical Industries Ltd (ADR) (TEVA) / Hydroxychloroquine Sulfate - Mylan Inc. (MYL) / Hydroxychloroquine Sulfate - Novartis AG (ADR) (NVS) / Sandoz Hydroxychloroquine Sulfate - Interpharm Holdings, Inc. (IPA) / Prednisone

6. Product Lifecycle

Sector and Product Hierarchy Path	Indications	Side Effects	Stage of Development
I Healthcare			
Biopharmaceuticals			
Cardiovascular System			
● Research/Preclinical Stage Products			
Dermatology			
▲ Lesion/Scaling Disorders			
▲ Pemphigus Vulgaris			
● Immunosuppressants			
Immunology			
▲ Autoimmune Disorders			
▲ Lupus Erythematosus			
▲ Systemic (SLE)			
● Immunosuppressants			
● Research/Preclinical Stage Products			
Neurology			
● Research/Preclinical Stage Products			
Transplantation			
▲ Heart			
▲ Rejection Prophylaxis			
● Immunosuppressants			
▲ Hepatic (Liver)			
▲ Rejection Prophylaxis			
● Immunosuppressants			
▲ Renal (Kidney)			
▲ Rejection Prophylaxis			
● Immunosuppressants			
CellCept (Mycophenolate Mofetil)	Prophylaxis Of Organ Rejection In Patients Receiving Allogeneic Renal, Cardiac Or Hepatic Transplants		Approved
CellCept (Mycophenolate Mofetil)	Cardiovascular Disease In Lupus Patients		Research
CellCept (Mycophenolate Mofetil)	Multiple Sclerosis (MS)		Research
CellCept (Mycophenolate Mofetil)	Multiple Sclerosis (MS)		Research
CellCept (Mycophenolate Mofetil)	Prophylaxis Of Organ Rejection In Patients Receiving Allogeneic Renal, Cardiac Or Hepatic Transplants		Approved
CellCept (Mycophenolate Mofetil)	Prophylaxis Of Organ Rejection In Patients Receiving Allogeneic Renal, Cardiac Or Hepatic Transplants		Approved
CellCept (Mycophenolate Mofetil)	Lupus Nephritis In Systemic Lupus Erythematosus (SLE)		Phase III
CellCept (Mycophenolate Mofetil)	Pemphigus Vulgaris		Phase III